Posted webinars are based on the talks and courses indicated.
Drug-like VHH from naive library selections
Here Andre describes the creation and validation of VHH libraries using the Generation 3 concept, that are able to yield high affinity VHHs directly from naive libraries
January 16, 2023 – January 20, 2023 | San Diego, CA, USA | Presented by Andre Teixeira
Antibody affinity and developability optimization with defined natural CDRs
In this webinar, Andrew describes the use of the Generation 3 antibody library concept to affinity maturation and developability improvement of antibodies.
January 16, 2023 – January 20, 2023 | San Diego, CA, USA | Presented by Andrew Bradbury
The Greatest Competition in the History of Antibody Discovery
The SARS-CoV-2 pandemic has resulted in an extraordinary worldwide unplanned experiment, in which numerous scientific groups have generated antibodies against a single target: the CoV-2 spike antigen, allowing the comparison of different methods and derived antibodies. The most potent neutralizing antibodies have been generated from convalescent patients and immunized animals, with non-immune phage libraries usually yielding significantly less potent antibodies. Here we show it is possible to generate ultra-potent (IC50 <1ng/ml) human neutralizing antibodies directly from a novel naïve antibody library format with affinities, developability properties and neutralization activities comparable to the best from hyperimmune sources
December 12, 2021 – December 16, 2021 | San Diego, CA, USA | Presented by Andrew Bradbury
Antibody discovery in the cloud: using NGS to expand the universe of selectable antibodies
The Specifica Generation 3 platform is able to generate 500-5000 different antibody clonotypes against targets of interest, with over 80% of selected antibodies having no measurable biophysical liabilities and 20% having subnanomolar affinities. The most common approach to selecting antibodies from display technologies involves low-throughput random colony screening. However, this misses many potential therapeutic leads, particularly when diversity is high. Specifica uses next generation sequencing (NGS) to build its libraries as well as characterize selection outputs. In order to fully exploit the universe of selectable antibodies, Specifica has developed a cloud-based software platform, designed exclusively for antibody engineers and bioinformaticians, to enable a streamlined identification of leads with broad epitope coverage. Application of this to selection outputs has increased the number of clonotype leads by five to ten fold over random colony screening, significantly expanding the explorable paratope spaces.
January 21, 2021 – January 21, 2021 | San Diego, CA, USA | Presented by Andrew Bradbury and Frank Erasmus